Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study.

Trial Profile

Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms RAL-eve
  • Most Recent Events

    • 31 Oct 2011 Planned End Date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Planned End Date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top